SCHEMBL18725442

SCHEMBL18725442

COC(=O)c1cc(Cl)c(C(F)F)cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 4/20 0.44
▸ ALDH1A1 P00352 2/20 0.43
▸ LCK P06239 1/20 0.42
▸ GABRP O00591 2/20 0.40
▸ GABRD O14764 2/20 0.40
▸ GABRA1 P14867 2/20 0.40
▸ GABRB1 P18505 2/20 0.40
▸ GABRG2 P18507 2/20 0.40
▸ GABRB3 P28472 2/20 0.40
▸ GABRA5 P31644 2/20 0.40
▸ GABRA3 P34903 2/20 0.40
▸ GABRA2 P47869 2/20 0.40
▸ GABRB2 P47870 2/20 0.40
▸ GABRA4 P48169 2/20 0.40
▸ GABRE P78334 2/20 0.40
▸ GABRA6 Q16445 2/20 0.40
▸ GABRG1 Q8N1C3 2/20 0.40
▸ GABRG3 Q99928 2/20 0.40
▸ GABRQ Q9UN88 2/20 0.40
▸ KDM4E B2RXH2 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30433741 0.84 MAPK1 (0.44) MAPK1ALDH1A1LCKGABRPGABRD
SCHEMBL18725412 0.84 MAPK1 (0.44) MAPK1ALDH1A1LCKGABRPGABRD
SCHEMBL21622928 0.84 MAPK1 (0.44) MAPK1ALDH1A1LCKGABRPGABRD
SCHEMBL29272500 0.83 MAPK1 (0.46) MAPK1ALDH1A1LCKGABRPGABRD
SCHEMBL17439992 0.83 GABRA1 (0.49) MAPK1ALDH1A1GABRPGABRDGABRA1
SCHEMBL29878585 0.82 MAPK1 (0.45) MAPK1ALDH1A1LCKGABRPGABRD
SCHEMBL19835436 0.81 MAPK1 (0.50) MAPK1ALDH1A1LCKGABRPGABRD
SCHEMBL21873493 0.78 LCK (0.53) MAPK1ALDH1A1LCKGABRPGABRD
SCHEMBL30031450 0.78 MAPK1 (0.47) MAPK1ALDH1A1LCKGABRPGABRD
SCHEMBL3936135 0.78 MAPK1 (0.47) MAPK1ALDH1A1LCKGABRPGABRD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552777-B2 Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2026-02-17 — — US disclosed
US-20240376079-A1 Apoptosis Signal-Regulating Kinase 1 Inhibitors and Methods of Use Thereof ENANTA PHARM INC (US) 2024-11-14 — — US disclosed
US-20240228464-A9 TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARM INC (US) 2024-07-11 — — US disclosed
US-12018017-B2 Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2024-06-25 — — US disclosed
US-12018017-B2 Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2024-06-25 — — US disclosed
US-11834436-B2 Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2023-12-05 — — US disclosed
EP-3621615-B1 APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARM INC (US) 2023-11-15 — — EP disclosed
EP-3621615-B1 APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARM INC (US) 2023-11-15 — — EP disclosed
US-20230174515-A1 APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARM INC (US) 2023-06-08 — — US disclosed
US-20230174515-A1 APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARM INC (US) 2023-06-08 — — US disclosed
US-20200331890-A1 APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF SILICON VALLEY BANK 2020-10-22 — — US disclosed
US-10683279-B2 Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2020-06-16 — — US disclosed
US-10683279-B2 Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2020-06-16 — — US disclosed
EP-3621615-A1 APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF Enanta Pharmaceuticals, Inc. (US) 2020-03-18 — — EP disclosed
CN-110869017-A Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof 英安塔制药有限公司 2020-03-06 — — CN disclosed
EP-3156397-B1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 — — EP disclosed
WO-2018209354-A1 APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. (US) 2018-11-15 — — WO disclosed
US-20180327388-A1 APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2018-11-15 — — US disclosed
US-20170121308-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-05-04 — — US disclosed
EP-3156397-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2017-04-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12552777-B2 Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof AIFM1, BAD, IRAK1 MAPK1 46/4885ALDH1A1 2450/4885LCK 304/4885
US-20240376079-A1 Apoptosis Signal-Regulating Kinase 1 Inhibitors and Methods of Use Thereof BAD, CASP1, BAX MAPK1 71/4885ALDH1A1 1882/4885LCK 230/4885
US-20170121308-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND CHRM1, CHRM5, CHRM2 MAPK1 708/4885ALDH1A1 2363/4885LCK 2008/4885
US-12018017-B2 Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof BAD, CASP1, BAX MAPK1 71/4885ALDH1A1 1882/4885LCK 230/4885
US-20180327388-A1 APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF BAD, CASP1, BAX MAPK1 71/4885ALDH1A1 1882/4885LCK 230/4885
US-11834436-B2 Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof AIFM1, BAD, IRAK1 MAPK1 83/4885ALDH1A1 1233/4885LCK 120/4885
US-20240228464-A9 TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF AIFM1, BAD, IRAK1 MAPK1 83/4885ALDH1A1 1233/4885LCK 120/4885
US-20200331890-A1 APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF BAD, CASP1, BAX MAPK1 71/4885ALDH1A1 1882/4885LCK 230/4885
US-10683279-B2 Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof BAD, CASP1, BAX MAPK1 71/4885ALDH1A1 1882/4885LCK 230/4885
US-20230174515-A1 APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF BAD, CASP1, BAX MAPK1 71/4885ALDH1A1 1882/4885LCK 230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback